Nab-paclitaxel
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DRUG-NAB-PACLITAXEL |
|---|---|
| Type | Médicament |
| Alias | ABI-007Acides aromatiquesNab-paclitaxel (paclittaxel lié à l'albumine)Paclitaxel lié à l'albumineНаб-паклітаксел |
| État | reviewed 2026-04-26 | pending_clinical_signoff |
| Maladies | DIS-NSCLC DIS-PDAC |
| Sources | SRC-NCCN-PANCREATIC-2025 |
Faits sur les drogues
| Catégorie | Taxane (stabilisateur de microtubules; formulation de nanoparticules reliées à l'albumine) |
|---|---|
| Mécanisme | Same active moiety as paclitaxel — binds β-tubulin and stabilizes microtubules, blocking mitotic progression. Solvent-free 130-nm nanoparticle formulation: paclitaxel non-covalently bound to human serum albumin. Eliminates Cremophor-EL → no Cremophor hypersensitivity → no corticosteroid / antihistamine premedication required and faster infusion (~30 min). Albumin binding may exploit gp60-mediated endothelial transcytosis and SPARC-mediated tumor accumulation (proposed; clinical relevance debated). Backbone of gem-nab-pac PDAC regimen (MPACT trial). |
| Dose typique | Pancreatic 1L gem-nab-pac (MPACT regimen): 125 mg/m² IV over 30-40 min days 1, 8, 15 of 28-day cycle, with gemcitabine 1000 mg/m². Breast metastatic: 260 mg/m² IV over 30 min q21d (mono). NSCLC (with carboplatin AUC 6): 100 mg/m² IV days 1, 8, 15 q21d. TNBC (IMpassion130, with atezolizumab): 100 mg/m² IV days 1, 8, 15 of 28-day cycle. No corticosteroid premedication required (vs Cremophor-paclitaxel). Day-15 dose held for ANC <1.0 / Plt <75 in PDAC schedule. |
| Ukraine enregistrée | Vrai |
| NSZU remboursé | Vrai |
| Ukraine vérifiée pour la dernière fois | 2026-04-27 |
Avertissements
- Severe myelosuppression (administration NOT recommended for ANC <1.5)
Notes
No corticosteroid premedication required (vs Cremophor paclitaxel), enabling outpatient infusion + reduced steroid exposure (relevant for diabetic and immunocompromised patients). Day-15 dose typically held for ANC <1.0 or platelets <75 in PDAC gem-nab-pac. PDAC eligibility: PS 0-1, bilirubin <2× ULN. MPACT trial: gem-nab-pac vs gem alone — mOS 8.5 vs 6.7 mo, ORR 23 vs 7%. Compared to FOLFIRINOX: gem-nab-pac better tolerated in older / frail / ECOG 1, FOLFIRINOX superior efficacy in fit ECOG 0. Hepatic dose adjustment: bilirubin 1.26-2.0× ULN reduce to 100 mg/m² (PDAC) or 200 mg/m² (breast); >2-5× ULN reduce to 75 mg/m² (PDAC) or 130 mg/m² (breast).
Utilisé par
Protocole thérapeutique
REG-GEM-NAB-PAC- Gemcitabine + nab-paclitaxel (MPACT)REG-PEMBRO-CARBO-NAB-PACLITAXEL-NSCLC-SQ- Pembrolizumab + carboplatin + nab-paclitaxel (squamous NSCLC, first line)